Multiple Myeloma
Conditions
Brief summary
This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.
Detailed description
Tasquinimod has previously been studied as an anti-cancer agent in patients with other cancers, including a phase 3 randomized trial in patients with metastatic prostate cancer that showed an improvement in radiographic progression-free survival. The side effect profile of tasquinimod is well-characterized based on this previous experience. This trial will establish a maximum tolerated dose and optimal schedule for administration of tasquinimod in patients with multiple myeloma and then investigate the maximum tolerated dose of tasquinimod in combination with a standard myeloma regimen of ixazomib, lenalidomide, and dexamethasone (IRd). For both single agent tasquinimod and the combination of tasquinimod with IRd, exploratory expansion cohorts will be enrolled to preliminarily characterize the antimyeloma activity of each regimen.
Interventions
DRUGTasquinimod
Tasquinimod will be supplied as oral capsules.
DRUGIRd chemotherapy
IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone
Sponsors
Active Biotech AB
University of Pennsylvania
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open label phase 1 study with pilot expansion cohorts at the maximum tolerated dose
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent 2. 18 years of age or older 3. Multiple myeloma (MM) diagnosed according to IMWG criteria 4. Measurable disease (this is defined differently in different arms) 5. Multiple myeloma relapsed or refractory to treatment (this is defined differently in different arms) 6. Meet certain clinical laboratory criteria 7. ECOG performance status ≤2 8. Life expectancy of at least 3 months 9. For women of childbearing potential, a negative serum or urine pregnancy test prior to study treatment. 10. For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two methods of contraception one of which must be highly effective 11. For men: agreement to use a barrier method of contraception for 1 month before start of study treatment, during the treatment period and for 6 months after the last dose of study treatment.
Exclusion criteria
1. Failure to have fully recovered (i.e. ≤ Grade 1 toxicity) from the effects of prior chemotherapy (except for alopecia) 2. Active graft versus host disease 3. Treatment with any of the following: 1. Cytotoxic chemotherapy within 3 weeks prior to the initiation of study treatment 2. Proteasome inhibitors, Imids, or monoclonal antibodies within 2 weeks prior to the initiation of study treatment 3. Experimental therapy within 4 weeks or 5 half-lives, whichever is shorter 4. Systemic corticosteroids \>=10 mg prednisone or equivalent within 7 days prior to the initiation of study treatment 5. Radiotherapy within 7 days prior to initiating study treatment 6. Plasmapheresis within 4 weeks prior to the initiation of study treatment 7. Tasquinimod at any time 4. Known central nervous system involvement by myeloma 5. Diagnosis of smoldering multiple myeloma 6. Diagnosis of POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) 7. Active plasma cell leukemia 8. Symptomatic primary (AL) amyloidosis 9. Diagnosis of myelodysplastic syndrome or myeloproliferative syndrome 10. Active other malignancy 11. Major surgery within 4 weeks prior to initiating study treatment 12. Evidence of severe or currently uncontrolled cardiovascular condition 13. Ongoing or active systemic infection that requires systemic antibiotic or parenteral anti-infective therapy 14. Active tuberculosis, active hepatitis A, B or C virus infection, or known human immunodeficiency virus (HIV) positive 15. History of pancreatitis 16. History of malabsorption or other condition that would interfere with absorption of study drugs 17. Systemic treatment within 14 days prior to the initiation of study treatment with moderate or strong inhibitor or moderate or strong inducer of cytochrome P-3A4 (CYP3A4) 18. Need for ongoing therapy drug substances of narrow therapeutic range that are metabolized mainly by CYP3A4 (alfentanil, fentanyl, quinidine, astemizole, terfenadine, sirolimus, tacrolimus, cyclosporine, cisapride, ergotamine) 19. Need for ongoing therapy with drug substances of narrow therapeutic range metabolized mainly by CYP1A2 (duloxetine, alosetron, theophylline, tizanidine, ondansetron) 20. Ongoing treatment with warfarin, unless the INR is \<=3.0. 21. For subjects enrolled on the IRd combination arms, prior dose-limiting toxicity with lenalidomide or ixazomib or absolute contraindication to concomitant thrombosis prophylaxis 22. Peripheral neuropathy grade ≥2 (NCI-CTCAE) 23. Known hypersensitivity to tasquinimod or any excipients in the study treatments 24. Pregnant or nursing (lactating) women 25. Any other condition that would, in the Investigator's judgment, contraindicate subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures 26. Prior inclusion in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Optimal Dose | approximately 3 years | Maximum tolerated dose of single agent tasquinimod (mg). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Preliminary Single-Agent Toxicity Profile | approximately 3 years | Percentage of subjects experiencing treatment-emergent grade 3/4 adverse events during therapy with single-agent tasquinimod (using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 5) |
| Preliminary Combination Therapy Toxicity Profile | approximately 3 years | Percentage of subjects experiencing treatment-emergent grade 3/4 adverse events during therapy with tasquinimod, ixazomib, lenalidomide, and dexamethasone (using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 5) |
| Preliminary Single-Agent Response | approximately 3 years | Percentage of subjects achieving a partial response or better with single-agent tasquinimod (using the response criteria of the International Myeloma Working Group) |
| Preliminary Assessment of Clinical Response Combination Therapy | approximately 3 years | Percentage of subjects achieving a partial response or better with tasquinimod, ixazomib, lenalidomide, and dexamethasone (using the response criteria of the International Myeloma Working Group) |
Countries
United States
Outcome results
None listed